These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8311115

  • 1. Expression and prognostic significance of apolipoprotein D in breast cancer.
    Díez-Itza I, Vizoso F, Merino AM, Sánchez LM, Tolivia J, Fernández J, Ruibal A, López-Otín C.
    Am J Pathol; 1994 Feb; 144(2):310-20. PubMed ID: 8311115
    [Abstract] [Full Text] [Related]

  • 2. Expression and clinical significance of apolipoprotein D in male breast cancer and gynaecomastia.
    Serra Díaz C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Baltasar A, Medrano J.
    Br J Surg; 1999 Sep; 86(9):1190-7. PubMed ID: 10504376
    [Abstract] [Full Text] [Related]

  • 3. Comparative study of two androgen-induced markers (apolipoprotein D and pepsinogen C) in female and male breast carcinoma.
    Serra C, Vizoso F, Lamelas ML, Rodríguez JC, González LO, Merino AM, Baltasar A, Pérez-Vázquez MT, Medrano J.
    Int J Surg Investig; 2000 Sep; 2(3):183-92. PubMed ID: 12678518
    [Abstract] [Full Text] [Related]

  • 4. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer.
    Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR.
    Cancer Res; 2002 Jun 15; 62(12):3417-27. PubMed ID: 12067984
    [Abstract] [Full Text] [Related]

  • 5. Expression and clinical significance of apolipoprotein D in epithelial ovarian carcinomas.
    Vázquez J, González L, Merino A, Vizoso F.
    Gynecol Oncol; 2000 Mar 15; 76(3):340-7. PubMed ID: 10684708
    [Abstract] [Full Text] [Related]

  • 6. Apolipoprotein D expression in metastasic lymph nodes of breast cancer.
    Lamelas ML, Vázquez J, Enguita MI, Rodríguez JC, González LO, Merino AM, Vizoso F.
    Int J Surg Investig; 2000 Mar 15; 2(4):285-93. PubMed ID: 12678530
    [Abstract] [Full Text] [Related]

  • 7. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.
    Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.
    Anticancer Res; 2004 Mar 15; 24(3b):2061-8. PubMed ID: 15274401
    [Abstract] [Full Text] [Related]

  • 8. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma.
    Di Saverio S, Gutierrez J, Avisar E.
    Breast Cancer Res Treat; 2008 Oct 15; 111(3):541-7. PubMed ID: 18026874
    [Abstract] [Full Text] [Related]

  • 9. Overexpression of matrix-metalloproteinase-9 in human breast cancer: a potential favourable indicator in node-negative patients.
    Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M.
    Br J Cancer; 2001 Jun 01; 84(11):1488-96. PubMed ID: 11384099
    [Abstract] [Full Text] [Related]

  • 10. Co-expression of estrogen receptor alpha and Apolipoprotein D in node positive operable breast cancer--possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients.
    Søiland H, Skaland I, Varhaug JE, Kørner H, Janssen EA, Gudlaugsson E, Baak JP, Søreide JA.
    Acta Oncol; 2009 Jun 01; 48(4):514-21. PubMed ID: 19107621
    [Abstract] [Full Text] [Related]

  • 11. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
    Sapino A, Righi L, Cassoni P, Papotti M, Gugliotta P, Bussolati G.
    Mod Pathol; 2001 Aug 01; 14(8):768-76. PubMed ID: 11504836
    [Abstract] [Full Text] [Related]

  • 12. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Rønne E, Dano K, Klijn JG, Brünner N, Foekens JA.
    Clin Cancer Res; 1995 Oct 01; 1(10):1079-87. PubMed ID: 9815897
    [Abstract] [Full Text] [Related]

  • 13. Apolipoprotein D predicts adverse outcome in women >or=70 years with operable breast cancer.
    Søiland H, Janssen EA, Kørner H, Varhaug JE, Skaland I, Gudlaugsson E, Baak JP, Søreide JA.
    Breast Cancer Res Treat; 2009 Feb 01; 113(3):519-28. PubMed ID: 18330697
    [Abstract] [Full Text] [Related]

  • 14. Flt-4-positive vessel density correlates with vascular endothelial growth factor-d expression, nodal status, and prognosis in breast cancer.
    Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K.
    Clin Cancer Res; 2003 Nov 01; 9(14):5313-7. PubMed ID: 14614015
    [Abstract] [Full Text] [Related]

  • 15. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma.
    Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E.
    Cancer; 2003 Mar 15; 97(6):1573-81. PubMed ID: 12627523
    [Abstract] [Full Text] [Related]

  • 16. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
    Foekens JA, Look MP, Bolt-de Vries J, Meijer-van Gelder ME, van Putten WL, Klijn JG.
    Br J Cancer; 1999 Jan 15; 79(2):300-7. PubMed ID: 9888472
    [Abstract] [Full Text] [Related]

  • 17. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer.
    Linjawi A, Kontogiannea M, Halwani F, Edwardes M, Meterissian S.
    J Am Coll Surg; 2004 Jan 15; 198(1):83-90. PubMed ID: 14698315
    [Abstract] [Full Text] [Related]

  • 18. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.
    Anticancer Res; 2004 Jan 15; 24(4):2391-400. PubMed ID: 15330189
    [Abstract] [Full Text] [Related]

  • 19. Prognostic value of prostate-specific antigen for women with breast cancer: a large United States cohort study.
    Yu H, Levesque MA, Clark GM, Diamandis EP.
    Clin Cancer Res; 1998 Jun 15; 4(6):1489-97. PubMed ID: 9626467
    [Abstract] [Full Text] [Related]

  • 20. Tissue-type plasminogen activator (tPA) in breast cancer: relationship with clinicopathological parameters and prognostic significance.
    Corte MD, Vérez P, Rodríguez JC, Roibás A, Domínguez ML, Lamelas ML, Vázquez J, García Muñiz JL, Allende MT, González LO, Fueyo A, Vizoso F.
    Breast Cancer Res Treat; 2005 Mar 15; 90(1):33-40. PubMed ID: 15770524
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.